Summit Therapeutics (SMMT) Q2 2026 earnings summary

Executive summary

• Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated statistically significant and clinically meaningful overall survival benefit in Phase III trials, including the HARMONI-6 trial for 1L squamous NSCLC, and consistent efficacy across Asian and Western populations in EGFR-mutated NSCLC post-TKI.

• Over 4,000 patients have been dosed in clinical trials globally, and more than 70,000 patients have received the drug commercially in China.

• Ivonescimab has received two approvals in China, with a pending BLA accepted by the FDA for EGFR-mutated NSCLC plus chemotherapy, and a PDUFA date set for November 14, 2026.

• The global clinical development plan includes multiple Phase III trials in lung, colorectal, head and neck, and other solid tumors, with ongoing collaborations with Akeso, RevMed, GSK, Arcus, and Revolution Medicines.

• Ivonescimab is positioned as a differentiated immunotherapy in the global oncology landscape, targeting a total addressable market exceeding $90 billion.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $690.7 million at June 30, 2026, with no debt.

• GAAP operating expenses for Q2 2026 were $220.5 million, up from $195.2 million in Q1 2026; non-GAAP operating expenses were $151.8 million, up from $122.4 million.

• GAAP net loss for Q2 2026 was $215.7 million ($0.28/share), improved from $565.7 million ($0.76/share) in Q2 2025; non-GAAP net loss was $147.0 million ($0.19/share) vs. $86.9 million ($0.12/share) in Q2 2025.

• Raised $230.8 million in Q2 2026 and $68.4 million post-quarter via ATM facility.

• Net cash used in operating activities for H1 2026 was $263.4 million.

Outlook and guidance

• FDA decision on BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC post-TKI therapy is expected by November 14, 2026.

• Commercial launch preparations are underway, with leadership, market access, and MSL teams in place; field force hiring planned closer to approval.

• Additional global Phase III studies in new tumor types and settings are planned, with updates and data from collaborations expected throughout 2026 and 2027.

• Cash and investments may be insufficient to fund operations for the next 12 months without additional capital; plans to raise funds through equity, debt, or collaborations.